Altamira Therapeutics LtdNASDAQ:CYTO
- LAST PRICE1.5000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4600/ 3
- Ask / Lots1.5000/ 10
- Open / Previous Close0.0000 / 1.5000
- Day Range---
- 52 Week Range
- Volume106
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYTO |
|---|---|---|
| 09:32 ET | 2427 | 1.45 |
| 09:36 ET | 500 | 1.48 |
| 09:41 ET | 400 | 1.4525 |
| 09:45 ET | 500 | 1.4765 |
| 09:50 ET | 475 | 1.46 |
| 09:57 ET | 100 | 1.46 |
| 10:01 ET | 275 | 1.455 |
| 10:15 ET | 200 | 1.475 |
| 10:32 ET | 100 | 1.455 |
| 10:50 ET | 976 | 1.42 |
| 10:55 ET | 300 | 1.425 |
| 11:00 ET | 900 | 1.4686 |
| 11:02 ET | 275 | 1.469 |
| 11:06 ET | 340 | 1.4627 |
| 11:15 ET | 100 | 1.42 |
| 11:20 ET | 340 | 1.4281 |
| 11:29 ET | 100 | 1.4584 |
| 11:38 ET | 500 | 1.445 |
| 11:40 ET | 800 | 1.46 |
| 11:54 ET | 100 | 1.445 |
| 11:58 ET | 201 | 1.45 |
| 12:07 ET | 100 | 1.465 |
| 01:30 ET | 500 | 1.4899 |
| 01:35 ET | 324 | 1.48 |
| 01:44 ET | 300 | 1.49 |
| 01:48 ET | 900 | 1.49 |
| 01:50 ET | 164 | 1.4977 |
| 01:51 ET | 191 | 1.499 |
| 01:53 ET | 1500 | 1.5 |
| 01:57 ET | 100 | 1.49 |
| 03:23 ET | 100 | 1.49 |
| 03:25 ET | 800 | 1.48 |
| 03:41 ET | 206 | 1.48 |
| 03:43 ET | 100 | 1.48 |
| 03:48 ET | 295 | 1.5185 |
| 03:54 ET | 2719 | 1.51 |
| 03:56 ET | 300 | 1.5 |
| 03:59 ET | 300 | 1.5 |
Apr 10, 2024
*DJ Altamira Therapeutics 2023 Loss/Shr CHF7.88 >CYTO, from 8:02AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:02AM ET on Wednesday Apr 10, 2024 by Dow JonesAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results, from 8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 4, 2024
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024, from 8:45AM ET on Thursday Apr 04, 2024 by Dow Jones
8:45AM ET on Thursday Apr 04, 2024 by Dow Jones
Mar 26, 2024
Thinking about buying stock in Equillium, Kuke Music, Altamira Therapeutics, MoneyHero, or Enerplus?, from 9:31AM ET on Tuesday Mar 26, 2024 by Dow Jones
9:31AM ET on Tuesday Mar 26, 2024 by Dow Jones
Mar 25, 2024
DJ Altamira Therapeutics Shares Jump on mRNA Vaccine Collaboration With Univercells, from 10:20AM ET on Monday Mar 25, 2024 by Dow Jones
10:20AM ET on Monday Mar 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Altamira Therapeutics Ltd | 3.4M | -0.1x | --- |
Revelation Biosciences Inc | 3.7M | 0.1x | --- |
Clearmind Medicine Inc | 3.7M | 0.0x | --- |
Biophytis SA | 3.6M | -0.2x | --- |
Mustang Bio Inc | 3.9M | -0.1x | --- |
GeoVax Labs Inc | 3.5M | -0.1x | --- |
Company Information
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, ZUG, Bermuda 6300
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.56 |
EPS | $-16.23 |
Book Value | $4.79 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
